In the past week, BDRX stock has gone up by 21.43%, with a monthly decline of -44.91% and a quarterly plunge of -43.33%. The volatility ratio for the week is 14.15%, and the volatility levels for the last 30 days are 15.53% for Biodexa Pharmaceuticals Plc ADR The simple moving average for the last 20 days is -16.69% for BDRX stock, with a simple moving average of -76.14% for the last 200 days.
Is It Worth Investing in Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) Right Now?
Moreover, the 36-month beta value for BDRX is 1.61. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
On March 19, 2025, BDRX’s average trading volume was 914.37K shares.
BDRX) stock’s latest price update
Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) has seen a rise in its stock price by 18.11 in relation to its previous close of 2.02. However, the company has experienced a 21.43% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-19 that CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).
Analysts’ Opinion of BDRX
Many brokerage firms have already submitted their reports for BDRX stocks, with Ladenburg Thalmann repeating the rating for BDRX by listing it as a “Buy.” The predicted price for BDRX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on February 08, 2024 of the previous year 2024.
BDRX Trading at -36.98% from the 50-Day Moving Average
After a stumble in the market that brought BDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.78% of loss for the given period.
Volatility was left at 15.53%, however, over the last 30 days, the volatility rate increased by 14.15%, as shares sank -44.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.36% lower at present.
During the last 5 trading sessions, BDRX rose by +20.85%, which changed the moving average for the period of 200-days by -90.13% in comparison to the 20-day moving average, which settled at $2.86. In addition, Biodexa Pharmaceuticals Plc ADR saw -41.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BDRX
Current profitability levels for the company are sitting at:
- -96.3 for the present operating margin
- -52.49 for the gross margin
The net margin for Biodexa Pharmaceuticals Plc ADR stands at -82.16. The total capital return value is set at -0.76. Equity return is now at value -96.61, with -61.80 for asset returns.
Based on Biodexa Pharmaceuticals Plc ADR (BDRX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -20.29.
Currently, EBITDA for the company is -7.16 million with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of -56.27. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
To wrap up, the performance of Biodexa Pharmaceuticals Plc ADR (BDRX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
